Tuesday, 16 Jul 2019

You are here

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.

These investigators have previously shown that the strong interaction between smoking and HLA-DRB1 SE has been confined to risk of seropositive RA.  In this study they further examined these risks based on RF and ACPA status.

This cohort study compared incident cases of RA (3645) and matched controls (5883) based on the presence or absence of RF and anti-CCP2 antibodies. They assessed the risk for RA using subgroups based on seropositivity, smoking and the SE.

Key findings showed the highest risk in:

  • Double positive (RF+/anti-CCP2+) patients were most affected as smoking and HLA-DRB1 SE conferred independent disease risks, and there was a strong interaction between the two risk factors.
  • RF-/anti-CCP2+ subset: HLA-DRB1 SE conferred an increased risk of RA whereas the independent influence of smoking was less, but there was a significant interaction between HLA-DRB1 and smoking.
  • In the RF+/anti-CCP2- subset, there was a smaller  increased risk in smokers, only marginally affected by HLA-DRB1 SE
  • Double negative (RF-/anti-CCP2-) subset, neither smoking nor HLA-DRB1SE conferred increased risk of disease.

These findings indicate weighted effects of smoking and HLA-DRB1, especially on seropositive RA patients. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CRP Utility in COPD Exacerbations

NEJM reports on the utility of C-reactive protein (CRP) testing in chronic obstructive pulmonary disease (COPD) patients, showing that CRP guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use.

EULAR 2019 - Day 1 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.

Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis

Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.

 

EULAR 2019 - Day 1 Report

Here are a few of the highlights from day 1 EULAR in Madrid. 

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis

 

Analysis of Rheumatoid Arthritis patients enrolled and treated as part of the British Society for Rheumatology Biologics Registry shows that sustained remission or low disease activity state (LDA) on TNF inhibitor treatment is uncommon and that combing methotrexate with an anti-TNF increases the odds of sustained remission/LDA.